SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares are trending amidst escalating global geopolitical tensions, particularly around Venezuela and Greenland, which is significantly boosting safe-haven demand. The community is actively discussing the impact of the ongoing Bloomberg Commodity Index rebalancing and expectations for potential dovish Federal Reserve policy. This confluence of factors reinforces gold's role as a hedge against broader economic uncertainty and currency debasement.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is experiencing significant market attention following positive interim clinical data for both its WVE-007 obesity program, which shows fat reduction with muscle preservation, and its WVE-006 program addressing alpha-1 antitrypsin deficiency. The community is actively discussing WVE-007's differentiated profile against current GLP-1 therapies, fueling high expectations for its potential to disrupt the weight loss market and attracting acquisition speculation despite its early development stage.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is actively trending amidst a highly contested Bloomberg Commodity Index rebalancing, which has sparked intense debate. Bulls largely dismiss the selling pressure, confidently accumulating shares due to robust industrial demand from sectors like AI and EVs, coupled with persistent supply deficits. Conversely, bears anticipate a significant downturn, drawing comparisons to historical market corrections and speculating on a potential "rug pull."

Memecoin on Injective taken over by the community.

Nonja

NONJA is gaining traction as a premier meme coin within the Injective ($INJ) ecosystem, amplified by strong community conviction and its proven resilience against market fluctuations. Investors are keenly discussing its 'unruggable' nature and high potential as a leveraged play on Injective's anticipated growth amid increasing institutional interest.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is a hot topic as it navigates headlines from a proposed credit card interest rate cap and a recent settlement in a 20-year legal battle over interchange fees. While these events fuel debate about potential impacts on the payment industry, many in the community are highlighting MA's resilient transaction-fee-based model and its strategic investments in AI-driven services and stablecoin integration for future growth.

Based Chad

CHAD CRYPTO is seeing increased conversation driven by notable engagement from Coinbase executives, including the Base lead developer, who are reportedly acquiring tokens and integrating CHAD within the Coinbase ecosystem. The community highlights its unique buyback mechanisms, staking opportunities, and resilient performance against market fluctuations, frequently calling it the "most popular meme in the world." This strong conviction on the Base network is further amplified by expectations of a supply shock and upcoming project developments.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is generating significant conversation around a proposed settlement concerning merchant interchange fees and ongoing policy discussions regarding credit card interest rate caps. While some investors anticipate potential headwinds, a strong counter-narrative emphasizes Visa's resilient transaction-based revenue model and its strategic expansion into stablecoin payments, positioning it as a steady long-term holding.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to a major agreement with Meta Platforms to develop 1.2 GW of nuclear energy for AI data centers, a deal seen as validating its advanced reactor technology. This significant collaboration, along with a new DOE agreement for a radioisotope pilot facility, has ignited strong community discussion around the stock's potential to meet future power demands and benefit from ongoing government support for the nuclear sector. While some express caution over its pre-revenue status and long-term deployment timelines, many view this as a pivotal moment for a company poised to capitalize on the AI-driven energy renaissance.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network (PI CRYPTO) is trending amid intense community debate over its prolonged pre-mainnet phase and perceived lack of progress towards a public launch. While many users voice frustration, branding the project a "scam" or "ad revenue scheme" due to locked balances and unverified tokens, a dedicated segment remains committed, continuing to mine and holding onto long-term aspirations for the cryptocurrency's future. The central discussion revolves around the network's long-term viability and whether it will ever fully materialize as a tradable asset.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending due to robust growth in its gross merchandise volume and U.S. revenue, driven by strong holiday season engagement and strategic advancements in AI-driven shopping. The community is actively discussing Klarna's bold push into stablecoins and its vision to become a leading digital bank, with many seeing it as an undervalued disruptor despite ongoing market scrutiny over broader consumer credit trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Wayne Pisano purchased 5,000 shares of Altimmune stock in a transaction on Thursday, January 8th. The stock was bought at an average price of...

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH

Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH. 

Why Are Investors Looking At Altimmune Stock?

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.read more...

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

<ul class="summary-bullets"><li>The drug, a 1:1 glucagon/GLP-1 dual-receptor agonist, targets patients with metabolic dysfunction-associated steatohepatitis (MASH).</li><li>Altimmune shared 48-week topline results in December 2025, indicating that continued pemvidutide treatment improved non-invasive tests.</li><li>The Phase-3 trial will test multiple pemvidutide doses over a 52-week treatment period.</li></ul>Altimmune, Inc. (ALT) announced on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) for its drug pemvidutide.The drug, a 1:1 glucagon/GLP-1 dual receptor agonist, targets patients suffering from metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition with limited treatment options.<h2 class="st-heading-2">How The Recognition Helps</h2>The designation is intended to boost the development and review of drugs that address serious or life-threatening illnesses and demonstrate early evidence of clinical benefit.&nbsp;The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis, along with improvements in liver fat and non-invasive fibrosis markers.<a href="https://stocktwits.com/symbol/ALT">Altimmune stock</a> traded over 14% higher in Monday’s premarket. However,&nbsp;on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘extremely low’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical Progress</h2>Altimmune shared 48-week topline results in December 2025, indicating that continued pemvidutide treatment improved non-invasive tests such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM) compared with placebo.&nbsp;Patients on the 1.8 mg dose experienced additional weight loss without a plateau, and the drug maintained a strong tolerability profile, with fewer discontinuations due to adverse events.<blockquote>“The FDA’s Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver disease.”-Jerry Durso, President and CEO, Altimmune</blockquote>Following a productive end-of-phase 2 meeting with the FDA, Altimmune finalized key parameters for a registrational Phase 3 trial in MASH patients with moderate-to-advanced liver fibrosis. The study will test multiple pemvidutide doses over a 52-week treatment period and incorporate biopsy-based results to support potential approval.&nbsp;ALT stock has declined by over 51% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-tsm-stock-jumping-over-3-premarket-today/cmxM1yjR4b0">Why Is TSM Stock Jumping Over 3% Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug 

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.

Equity

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.


3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Altimmune (NASDAQ:ALT) Director John Gill Purchases 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director John Gill bought 12,500 shares of the business's stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average cost of...

John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director John Gill purchased 12,500 shares of the business's stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat reports...

Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Jerome Benedict Durso acquired 12,500 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was purchased at an...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALT News

ALTAltimmune Inc